Aspect Medical Systems’s CFO to resign
Until a successor is elected, Mr Falvey’s responsibilities will be assumed by Neal Armstrong, who served as Aspect’s CFO from 1996 to 2005. Mr Falvey will assist Mr
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
The Acord trial will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Approximately 30 sites are expected to participate. CardioVascular BioTherapeutics’s